The Zika virus is an emerging threat in South American and equatorial countries around the planet. Initially disregarded as a serious threat to human health, Zika has now been linked to a rise in severe birth defects such as microcephaly (malformation of the head) and malformation of the brain. The disease is spread through the bite of an infected mosquito, causing the most significant problems for pregnant women. For others, it is generally no more problematic than a cold. It is seen as a potential global health crisis with the world descending on Brazil for the 2016 Summer Olympic Games.
As the disease and its effects are becoming better understood, government agencies, academic laboratories and biotechnology companies alike are racing for a viable course of treatment. One of the most sought after methods for eradicating Zika has been the development of a prophylactic vaccine. No such treatment opportunities currently exist.
While structural elements of the viral capsid are beginning to be elucidated, NanoCliq stands poised to aid your enterprise rapidly test viral protein epitopes. Whether your laboratory is looking at structural or nonstructural related proteins, such as NS1, NanoCliq can assist you in determining viable candidates for vaccine development.
NanoCliq’s offered services will allow for the testing of a panel of protein epitopes of interest for immunoglobulin response, pharmacology and toxicology. In addition, with the recently reported first successful cloning of the Zika virus in a laboratory setting, potential candidates can be administered in an animal model where the animal is challenged with the infectious disease. Speak with our team of scientists who can aid in your development of what stands to be the next significant breakthrough in vaccine treatment.